arrow
A

A. Vergnenègre

université de rennes
H指数:39
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (vol 5, 17499, 2015)
2023-03-030
OAAI
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

在治疗失败的晚期实体瘤患者中通过高通量测序确定的分子改变的临床管理: 来自法国医院的真实数据

2023-02-275
OAAI
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus at progression cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
2021-04-162
OAAI
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
2020-10-011.1K
OA
Platin pemetrexed with or without bevacizumab with upfront versus at progression brain radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis: A randomized phase III trial (Metal2 trial)
2020-09-011
OAAI
IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC
2020-04-156
OAAI
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Nivolumab联合Ipilimumab治疗晚期非小细胞肺癌

2019-11-212.0K
OAAI
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
2017-03-31131
OAAI
Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients
2016-07-150
PRE
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
2015-12-0763
OAAI